GLP-1 Receptor Agonists Semaglutide and tirzepatide are technically peptide-based therapeutics
Join Trial Testing New Drug for Weight Management A clinical trial is recruiting adults with type 2 diabetes to test a new long-lasting amylin drug for weight management
Combines four well-researched peptides Comes in COA-verified lyophilized powder form for purity and stability $140.00Purchase & earn 140 points
SubQ offers stable, extended release
Glutathione is a naturally occurring compound found in the body and involved in normal cellular processes related to antioxidant balance
This is the first study to show a clear benefit of GLP-1 receptor agonists on kidney failure or end-stage kidney disease, suggesting they have a key role in kidney-protective and heart-protective treatment for patients with common medical conditions like type 2 diabetes, overweight or obesity with cardiovascular disease, or CKD [chronic kidney disease], said lead author Sunil Badve, professorial fellow at The George Institute for Global Health and UNSW Sydney